-+ 0.00%
-+ 0.00%
-+ 0.00%

Molecular Partners Highlights MP0712 Tumor Uptake With Limited Healthy Tissue Uptake In First Patient Data At TWC 2026, Advancing DLL3-Targeted Alpha Therapy Strategy

Benzinga·02/02/2026 06:41:24
Listen to the news
  • Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancers
  • Dosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumors
  • MP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026
  • Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D.